全文获取类型
收费全文 | 62217篇 |
免费 | 4708篇 |
国内免费 | 1915篇 |
专业分类
耳鼻咽喉 | 344篇 |
儿科学 | 1080篇 |
妇产科学 | 615篇 |
基础医学 | 8054篇 |
口腔科学 | 753篇 |
临床医学 | 3733篇 |
内科学 | 9917篇 |
皮肤病学 | 1220篇 |
神经病学 | 5672篇 |
特种医学 | 775篇 |
外国民族医学 | 5篇 |
外科学 | 5267篇 |
综合类 | 5370篇 |
现状与发展 | 4篇 |
预防医学 | 2529篇 |
眼科学 | 732篇 |
药学 | 14218篇 |
12篇 | |
中国医学 | 1813篇 |
肿瘤学 | 6727篇 |
出版年
2024年 | 153篇 |
2023年 | 1391篇 |
2022年 | 2632篇 |
2021年 | 2748篇 |
2020年 | 2257篇 |
2019年 | 2571篇 |
2018年 | 2322篇 |
2017年 | 2274篇 |
2016年 | 1900篇 |
2015年 | 2154篇 |
2014年 | 3059篇 |
2013年 | 4653篇 |
2012年 | 2858篇 |
2011年 | 3477篇 |
2010年 | 2854篇 |
2009年 | 2787篇 |
2008年 | 2865篇 |
2007年 | 2626篇 |
2006年 | 2439篇 |
2005年 | 2030篇 |
2004年 | 1900篇 |
2003年 | 1698篇 |
2002年 | 1305篇 |
2001年 | 1002篇 |
2000年 | 1017篇 |
1999年 | 855篇 |
1998年 | 881篇 |
1997年 | 780篇 |
1996年 | 682篇 |
1995年 | 623篇 |
1994年 | 541篇 |
1993年 | 523篇 |
1992年 | 506篇 |
1991年 | 447篇 |
1990年 | 388篇 |
1989年 | 357篇 |
1988年 | 288篇 |
1987年 | 302篇 |
1986年 | 268篇 |
1985年 | 550篇 |
1984年 | 647篇 |
1983年 | 428篇 |
1982年 | 493篇 |
1981年 | 433篇 |
1980年 | 378篇 |
1979年 | 351篇 |
1978年 | 301篇 |
1977年 | 202篇 |
1976年 | 183篇 |
1975年 | 141篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Laura Airas 《Leukemia & lymphoma》1998,29(1):37-47
CD73, otherwise known as ecto-5'-nucleotidase, is a lymphocyte maturation marker which is involved in intracellular signalling, lymphocyte proliferation and activation. In addition, we have demonstrated that CD73 is involved in mediating lymphocyte binding to in vitro cultured endothelial cells and in controlling adhesion between freshly isolated germinal center B-cells and follicular dendritic cells (FDC). In secondary lymphoid tissues, CD73 is expressed on FDC in the light zone of the germinal center as well as on small, resting mantle zone B-cells but not on B-cells within germinal centers. In this review article, the potential role of CD73 in controlling B-cell-FDC interactions and B-cell maturation will be discussed. 相似文献
992.
U. Klaassen H. Wilke A. Harstrick C. Philippou Pari D. Strumberg K. Neumann W. Eberhardt W. Achterrath L. Lenaz S. Seeber 《Annals of oncology》1998,9(1):45-50
Purpose: To evaluate the antitumor activity in terms of response rate (RR), time to progression (TTP) and survival of paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil (5-FU)/leucovorin in pretreated metastatic breast cancer (MBC).Patients and methods: Fifty-four patients with bidimensionally measureable disease were included during phase II. Thirty-two had anthracycline resistant disease. Treatment consisted of 5-FU (24-hour i.v. infusion) 2.0 g/m2, leucovorin (two-hour i.v. infusion prior to 5-FU) 500 mg/m2, weekly for six weeks (day 1, 8, 15, 22, 29, 36) and paclitaxel (three-hour i.v. infusion) 175 mg/m2 was administered additionally on days 1 and 22, q 50 days.Results: We observed complete remissions in 4% of patients (2 of 54), partial remissions in 55% (30 of 54), stable disease in 37% (20 of 54) and progressive disease in 4% (2 of 54). The overall RR was 59% (95% CI 48%–72%). The RR in 32 patients with anthracycline resistant disease was 59% (19 of 32). The median duration of response was 12 months (3–22), median TTP eight months (2–22) and median survival time 15 months (2–28). Neutropenia was common, but of CTC grade 2 or 3 in most patients. Nonhematologic toxicities mostly consisted of CTC grade 1 and 2 myalgia, diarrhea, mucosits, nausea and vomiting.Conclusions: Paclitaxel combined with weekly 24-hour infusional 5-FU/leucovorin is well tolerated in the second line treatment of MBC. High efficacy was documented even in the treatment of anthracycline resistant disease, which warrants further evaluation. 相似文献
993.
Silvana Chiara Maria Teresa Nobile Maura Vincenti Rita Lionetto Alberto Gozza Maria Cristina Barzacchi Ornella Sanguineti Lazzaro Repetto Riccardo Rosso 《Cancer chemotherapy and pharmacology》1998,42(4):336-340
To evaluate toxicity and efficacy of chemotherapy in elderly patients (≥65 years of age) with advanced colorectal cancer,
data from two consecutive trials conducted between 1984 and 1995 at the National Institute for Cancer Research were analysed
comparing the results of treatment in those 65 years of age or older and in those younger than 65 years. Of 215 patients recruited,
82 elderly patients (median age 70 years, median performance status 1) received one of the following regimens based on 5-fluorouracil
(5-FU): (1) weekly 5-FU 600 mg/m2 i.v. bolus (30 patients); (2) weekly 5-FU 600 mg/m2 bolus plus leucovorin (LV) 500 mg/m2 2-h i.v. infusion (28 patients); (3) Weekly 5-FU 2600 mg/m2 24-h continuous i.v. infusion plus LV 100 mg 4-h i.v. infusion and 50 mg orally every 4 h for five doses (24 patients). Overall,
1071 chemotherapy cycles were administered with a median number of 12 courses per patient. The main side effects were diarrhoea,
observed in 38% of patients, stomatitis in 24% of patients and hand-foot syndrome in 13% of patients, and haematological toxicity
affected only 15% of patients. No patient suffered grade IV toxicity. In three patients chemotherapy was discontinued because
of toxicity (two patients suffered grade III diarrhoea, one patient grade III hand-foot syndrome). No significant difference
in toxicity was evident between patients older than or younger than 65 years. Analysis of median dose intensity demonstrated
no difference between the two groups. Overall objective response was observed in 18% (95% confidence limits 11–29) of elderly
patients (15/82) in comparison with 23% (95% CL 17–32) of patients <65 years of age (31/133 pts). In conclusion, chemotherapy
in elderly patients with advanced colorectal cancer is a safe and effective treatment with acceptable toxicity and comparable
objective response rates.
Received: 6 January 1998 / Accepted: 27 February 1998 相似文献
994.
S.A. Aziz N.A. Tramboo K. Mohi-ud-Din K. Iqbal S. Jalal M. Ahmad 《Clinical oncology (Royal College of Radiologists (Great Britain))》1998,10(6):377-378
5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens. Gastrointestinal toxicity and myelosuppression are the most common adverse reactions, but, of late, clinical cardiotoxicity has been reported in both prospective and retrospective studies. We present our experience of clinical cardiotoxicity in five patients. 相似文献
995.
目的探讨放疗联合化疗治疗复发直肠癌的临床效果。方法对29例根治术后复发的直肠癌进行了放射治疗,其中16例同时给予大剂量醛氢叶酸(CF),氟脲嘧啶(5FU)的全身化疗(观察组),13例为单纯放疗(对照组)。结果观察组中局部症状缓解率较对照组高,两组有效率分别为81.25%、46.16%,有显著性差异(P<0.05),完全缓解分别为18.75%、7.69%。两组放疗引起的局部毒性反应相似。结论CF/5Fu配合放射治疗复发直肠癌可提高近期疗效,尤其对于伴远外转移患者为理想、安全的治疗手段。 相似文献
996.
997.
998.
腺病毒介导的大肠杆菌CD自杀基因体内外对肿瘤杀伤作用的研究 总被引:1,自引:0,他引:1
编委会 Editorial Board名誉主编 Honorary Editor-in-chief吴孟超 Wu Meng chao(Second Military Medical University,Shanghai 200433学术顾问 Academic Advisers巴德年 Ba Denian(Chinese Academy of Medical Sciences,Beijing 100730)刘新垣 Liu Xinyuan(Shanghai Institute of Biochemistry,Chinese Academy of Sciences,Shanghai 200031)吴旻 WuMin(Cancer Institute,Chinese Academy of Medical Sciences,Beijing 100021)汤钊猷 Tang Zhaoyou(Shanghai Medical University,Shanghai 200032)主编 Editor-in-chief张友会 Zhang Youhui(Cancer Institute,Chinese Academy of Medical Sciences,Beijing,100021)副主编 Associate Editor-in-chief崔正言 Cul Zhenyan(Department of Immunology,Shandong Academy of Medical Sciences,Jinan 250001)钱振超 Qian Zhenchao(Department of Patho-physiology,Dalian Medical University,Dalian 116027)何球藻 He Qiuzao(Department of Immunology,Shanghai Medical University,Shanghai 200032)董志伟 Dong Zhiwei(Cancer Institute,Chinese Academy of Medical Sciences,Beijing 100021)常务副主编 Managing Editor-in-chief 相似文献
999.
[目的]探讨影响肺癌长期生存的因素。方法对1983年1月至1992年12月间收治的经病理证实的存活5年以上的72例肺癌患者进行分析。放疗采用60Co-r线或10MV-X线,大野前后对穿照射Dr40Gy/20次,共4周后缩野加量至总DT52G6y-76Gy(平均61.6Gy,非手术者)或50Gy-70Cy(平均56.1Gy,手术者)。手术均为肺叶(段)切除术。化疗主要方案为(CTX+5-FU+VCR、CTX+ADM+DDP、CTX+5-FU+CBP/E-ADM+VP-16等。[结果]临床分期、病理类型和是否加用手术治疗对5年生存率的影响,分析显示有统计学差异。I、II、III、IV期5年生存率分别为42.9%、12.9%、5.8%及0;小细胞未分化癌与非小细胞癌的5年生存率分别为3.2%和96%;手术加放疗(加或不加化疗)与放疗(加或不加化疗)的5年生存率分别为对.5%和5.5%。而放疗剂量及是否加化疗对5年生存率的影响未显示有统计学差异。[结论]肺癌应进行早期诊断、早期治疗,尽量采取以手术为主的综合治疗,以提高远期生存率。 相似文献
1000.